JANX — Janux Therapeutics Share News
0.000.00%
Last trade - 00:00- $1.04bn
- $72.08m
- $10.00m
Janux Therapeutics Q2 net loss narrows as expenses fall
Brief: Janux Therapeutics Q2 Basic EPS USD -0.35
Janux Therapeutics Q1 net loss widens on higher expenses
Brief: Janux Therapeutics Q1 Basic EPS USD -0.39
Brief: Janux Therapeutics Announces First Participant Dosed In Phase 1 Study Of Janx014
U.S. STOCKS ON THE MOVE-Eli Lilly, Space stocks, Anixa Biosciences
U.S. STOCKS ON THE MOVE-Intel, Tempus AI, Boeing
U.S. STOCKS ON THE MOVE-Cal-Maine, Rivian, Alkermes
Brief: Janux Therapeutics Announces Development Candidate Nomination Under Bristol Myers Squibb Collaboration
Janux Therapeutics up after nominating cancer therapy in Bristol Myers deal
Janux Therapeutics Q4 net loss widens on higher R&D expenses
Brief: Janux Therapeutics Q4 Basic EPS USD -0.51
Brief: Janux Therapeutics Announces First Patient Dosed In Phase 1 Study Of Janx011
U.S. STOCKS ON THE MOVE-Tesla, JPMorgan, Intel
U.S. STOCKS ON THE MOVE-Autodesk, Teledyne, Alphabet
U.S. STOCKS ON THE MOVE- Medicus Pharma, Lam Research, Applied Digital
Janux Therapeutics, Bristol Myers enter up to $850 million deal to develop cancer drug
Janux shares rise on global cancer drug deal with Bristol Myers
Brief: Janux Therapeutics, Bristol Myers Squibb Sign Exclusive Global License To Develop Tumor-Activated Solid Tumor Therapy